Bristol`s drug cocktail cuts kidney cancer death risk 37 percent

A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. More »